Paricalcitol for secondary hyperparathyroidism in renal transplantation

Matias Trillini, Monica Cortinovis, Piero Ruggenenti, Jorge Reyes Loaeza, Karen Courville, Claudia Ferrer-Siles, Silvia Prandini, Flavio Gaspari, Antonio Cannata, Alessandro Villa, Annalisa Perna, Eliana Gotti, Maria Rosa Caruso, Davide Martinetti, Giuseppe Remuzzi, Norberto Perico

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 μg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7) pg/ml (P

Original languageEnglish
Pages (from-to)1205-1214
Number of pages10
JournalJournal of the American Society of Nephrology
Volume26
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Secondary Hyperparathyroidism
Parathyroid Hormone
Kidney Transplantation
Proteinuria
Minerals
Serum
Calcitriol Receptors
Transplants
Kidney
Bone and Bones
Therapeutics
paricalcitol

ASJC Scopus subject areas

  • Nephrology

Cite this

Trillini, M., Cortinovis, M., Ruggenenti, P., Loaeza, J. R., Courville, K., Ferrer-Siles, C., ... Perico, N. (2015). Paricalcitol for secondary hyperparathyroidism in renal transplantation. Journal of the American Society of Nephrology, 26(5), 1205-1214. https://doi.org/10.1681/ASN.2013111185

Paricalcitol for secondary hyperparathyroidism in renal transplantation. / Trillini, Matias; Cortinovis, Monica; Ruggenenti, Piero; Loaeza, Jorge Reyes; Courville, Karen; Ferrer-Siles, Claudia; Prandini, Silvia; Gaspari, Flavio; Cannata, Antonio; Villa, Alessandro; Perna, Annalisa; Gotti, Eliana; Caruso, Maria Rosa; Martinetti, Davide; Remuzzi, Giuseppe; Perico, Norberto.

In: Journal of the American Society of Nephrology, Vol. 26, No. 5, 01.05.2015, p. 1205-1214.

Research output: Contribution to journalArticle

Trillini, M, Cortinovis, M, Ruggenenti, P, Loaeza, JR, Courville, K, Ferrer-Siles, C, Prandini, S, Gaspari, F, Cannata, A, Villa, A, Perna, A, Gotti, E, Caruso, MR, Martinetti, D, Remuzzi, G & Perico, N 2015, 'Paricalcitol for secondary hyperparathyroidism in renal transplantation', Journal of the American Society of Nephrology, vol. 26, no. 5, pp. 1205-1214. https://doi.org/10.1681/ASN.2013111185
Trillini M, Cortinovis M, Ruggenenti P, Loaeza JR, Courville K, Ferrer-Siles C et al. Paricalcitol for secondary hyperparathyroidism in renal transplantation. Journal of the American Society of Nephrology. 2015 May 1;26(5):1205-1214. https://doi.org/10.1681/ASN.2013111185
Trillini, Matias ; Cortinovis, Monica ; Ruggenenti, Piero ; Loaeza, Jorge Reyes ; Courville, Karen ; Ferrer-Siles, Claudia ; Prandini, Silvia ; Gaspari, Flavio ; Cannata, Antonio ; Villa, Alessandro ; Perna, Annalisa ; Gotti, Eliana ; Caruso, Maria Rosa ; Martinetti, Davide ; Remuzzi, Giuseppe ; Perico, Norberto. / Paricalcitol for secondary hyperparathyroidism in renal transplantation. In: Journal of the American Society of Nephrology. 2015 ; Vol. 26, No. 5. pp. 1205-1214.
@article{01ebd1b2a0b349b89193b19fbdd4e79e,
title = "Paricalcitol for secondary hyperparathyroidism in renal transplantation",
abstract = "Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 μg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7) pg/ml (P",
author = "Matias Trillini and Monica Cortinovis and Piero Ruggenenti and Loaeza, {Jorge Reyes} and Karen Courville and Claudia Ferrer-Siles and Silvia Prandini and Flavio Gaspari and Antonio Cannata and Alessandro Villa and Annalisa Perna and Eliana Gotti and Caruso, {Maria Rosa} and Davide Martinetti and Giuseppe Remuzzi and Norberto Perico",
year = "2015",
month = "5",
day = "1",
doi = "10.1681/ASN.2013111185",
language = "English",
volume = "26",
pages = "1205--1214",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Paricalcitol for secondary hyperparathyroidism in renal transplantation

AU - Trillini, Matias

AU - Cortinovis, Monica

AU - Ruggenenti, Piero

AU - Loaeza, Jorge Reyes

AU - Courville, Karen

AU - Ferrer-Siles, Claudia

AU - Prandini, Silvia

AU - Gaspari, Flavio

AU - Cannata, Antonio

AU - Villa, Alessandro

AU - Perna, Annalisa

AU - Gotti, Eliana

AU - Caruso, Maria Rosa

AU - Martinetti, Davide

AU - Remuzzi, Giuseppe

AU - Perico, Norberto

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 μg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7) pg/ml (P

AB - Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 μg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7) pg/ml (P

UR - http://www.scopus.com/inward/record.url?scp=84929377103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929377103&partnerID=8YFLogxK

U2 - 10.1681/ASN.2013111185

DO - 10.1681/ASN.2013111185

M3 - Article

C2 - 25194004

AN - SCOPUS:84929377103

VL - 26

SP - 1205

EP - 1214

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -